Ekene Ada Enemchukwu, MD
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Office
- 1
Offices
1 location
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Enemchukwu’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A136792 · Current
Licensed to practise in California · since 2015 · expires 2026-12-31 · University of North Carolina at Chapel Hill.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$55,943
Medicare paid this office $55,943 for 190 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| New patient visit (60+ min) | 72 | $11,225 | $156 |
| Return visit (30+ min) | 56 | $6,037 | $101 |
| Long return visit (40+ min) | 38 | $5,738 | $133 |
| Exam with injections of chemical for destruction of bladder using an endoscope | 12 | $2,209 | $147 |
| New patient visit (45+ min) | 13 | $1,350 | $104 |
See all 6 services
| New patient visit (60+ min) | 72 | $11,225 | $156 |
| Return visit (30+ min) | 56 | $6,037 | $101 |
| Long return visit (40+ min) | 38 | $5,738 | $133 |
| Exam with injections of chemical for destruction of bladder using an endoscope | 12 | $2,209 | $147 |
| New patient visit (45+ min) | 13 | $1,350 | $104 |
| Diagnostic exam of bladder and urethra using an endoscope | 16 | $1,058 | $62 |
Who their Medicare patients are
190 Original Medicare patients in 2024. Average age 73 · Under 65 13% · 85 and older 8% · Women 76% · Also on Medicaid 19% · Health risk score 1.51. Above the middle of the specialty; the typical urology clinician is at 1.36.
Conditions among them: High blood pressure 65% · Depression 27% · Diabetes 26% · Coronary heart disease 21% · Cancer 21% · Chronic kidney disease 17% · Atrial fibrillation 17% · Heart failure 12% · COPD 11% · Dementia 9% · Stroke 7%.
The office billed $863,667, Medicare allowed $72,635 and paid $55,943; for 403 services of 59 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 190 | 403 | 73 | 1.51 | $863,667 | $55,943 |
| 2023 | 113 | 224 | 73 | 1.48 | $362,035 | $35,701 |
| 2022 | 215 | 508 | 73 | 1.23 | $551,106 | $55,282 |
| 2021 | 156 | 320 | 74 | 1.41 | $362,155 | $34,479 |
| 2020 | 208 | 539 | 71 | 1.72 | $415,481 | $49,466 |
| 2019 | 352 | 1,040 | 72 | 1.53 | $567,088 | $86,616 |
| 2018 | 197 | 509 | 72 | 1.96 | $289,863 | $42,063 |
| 2017 | 283 | 1,080 | 71 | 1.82 | $645,188 | $84,990 |
| 2016 | 266 | 954 | 71 | 1.58 | $597,881 | $76,683 |
| 2015 | 79 | 241 | 73 | 1.33 | $121,679 | $18,885 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| New patient visit (60+ min) | 23 | $3,749 | $163 |
| Exam with injections of chemical for destruction of bladder using an endoscope | 18 | $2,558 | $111 |
| Return visit (30+ min) | 28 | $2,408 | $73 |
| Long return visit (40+ min) | 20 | $2,259 | $108 |
2022: 13 services
| Long return visit (40+ min) | 50 | $6,738 | $116 |
| New patient visit (60+ min) | 40 | $6,342 | $159 |
| Return visit (30+ min) | 53 | $4,543 | $74 |
| New patient visit (45+ min) | 34 | $3,519 | $104 |
| Exam with injections of chemical for destruction of bladder using an endoscope | 20 | $2,631 | $91 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 11 | $1,139 | $95 |
| Diagnostic exam of bladder and urethra using an endoscope | 13 | $783 | $60 |
| Insertion of device into abdomen with pressure and urine flow rate study | 11 | $360 | $30 |
| Review by radiologist of urinary bladder and urethra images with contrast and after passing urine | 11 | $172 | $14 |
| Review by radiologist of urinary bladder image | 11 | $169 | $14 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 11 | $169 | $14 |
| Electronic assessment of bladder emptying | 20 | $105 | $5 |
| Electronic assessment of bladder emptying | 11 | $46 | $4 |
2021: 7 services
| New patient visit (45+ min) | 40 | $4,615 | $115 |
| Return visit (30+ min) | 26 | $2,540 | $88 |
| New patient visit (60+ min) | 15 | $2,521 | $168 |
| Long return visit (40+ min) | 13 | $1,797 | $128 |
| Diagnostic exam of bladder and urethra using an endoscope | 19 | $1,301 | $68 |
| Short return visit (20+ min) | 14 | $740 | $53 |
| Short return visit (20+ min) | 11 | $259 | $24 |
2020: 16 services
| New patient visit (45+ min) | 31 | $2,991 | $96 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 20 | $2,368 | $118 |
| New patient visit (45+ min) | 17 | $1,946 | $114 |
| Return visit (30+ min) | 25 | $1,783 | $64 |
| Short return visit (20+ min) | 35 | $1,669 | $43 |
| Diagnostic exam of bladder and urethra using an endoscope | 18 | $1,434 | $75 |
| Return visit (30+ min) | 20 | $1,405 | $64 |
| Short return visit (20+ min) | 25 | $1,274 | $44 |
| Diagnostic exam of bladder and urethra using an endoscope | 14 | $892 | $64 |
| Insertion of device into abdomen with pressure and urine flow rate study | 20 | $749 | $37 |
| Short return visit | 22 | $524 | $22 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 20 | $355 | $18 |
| Review by radiologist of urinary bladder and urethra images with contrast and after passing urine | 23 | $353 | $15 |
| Review by radiologist of urinary bladder image | 21 | $316 | $15 |
| Injection procedure for imaging of bladder during voiding | 12 | $247 | $21 |
| Electronic assessment of bladder emptying | 25 | $125 | $5 |
2019: 23 services
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 11 | $7,440 | $676 |
| New patient visit (45+ min) | 63 | $6,662 | $106 |
| New patient visit (45+ min) | 62 | $6,370 | $103 |
| Return visit (30+ min) | 64 | $4,486 | $62 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 39 | $4,322 | $111 |
| Diagnostic exam of bladder and urethra using an endoscope | 57 | $3,480 | $60 |
| Return visit (30+ min) | 42 | $3,435 | $65 |
| Short return visit (20+ min) | 64 | $2,971 | $44 |
| New patient visit (60+ min) | 18 | $2,668 | $148 |
| Exam with injections of chemical for destruction of bladder using an endoscope | 16 | $2,406 | $127 |
| New patient visit (60+ min) | 18 | $1,984 | $110 |
| Diagnostic exam of bladder and urethra using an endoscope | 24 | $1,730 | $64 |
| Long return visit (40+ min) | 17 | $1,591 | $94 |
| Short return visit (20+ min) | 30 | $1,521 | $43 |
| Insertion of device into abdomen with pressure and urine flow rate study | 40 | $1,461 | $37 |
| Long return visit (40+ min) | 15 | $1,248 | $78 |
| Injection procedure for imaging of bladder during voiding | 37 | $786 | $21 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 40 | $681 | $17 |
| Review by radiologist of urinary bladder image | 39 | $598 | $14 |
| Review by radiologist of urinary bladder and urethra images with contrast and after passing urine | 39 | $566 | $14 |
| Short return visit | 14 | $300 | $21 |
| Electronic assessment of bladder emptying | 49 | $212 | $4 |
| Electronic assessment of bladder emptying | 24 | $164 | $6 |
2018: 17 services
| Return visit (30+ min) | 55 | $4,022 | $64 |
| New patient visit (45+ min) | 22 | $2,332 | $106 |
| Return visit (30+ min) | 29 | $1,951 | $61 |
| New patient visit (60+ min) | 12 | $1,742 | $145 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 17 | $1,665 | $98 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 11 | $1,405 | $128 |
| Diagnostic exam of bladder and urethra using an endoscope | 24 | $1,375 | $55 |
| New patient visit (45+ min) | 16 | $1,364 | $85 |
| Long return visit (40+ min) | 11 | $991 | $90 |
| Short return visit (20+ min) | 18 | $823 | $41 |
| Insertion of device into abdomen with pressure and urine flow rate study | 21 | $742 | $35 |
| Short return visit (20+ min) | 13 | $578 | $41 |
| Injection procedure for imaging of bladder during voiding | 22 | $429 | $19 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 20 | $324 | $16 |
| Review by radiologist of urinary bladder and urethra images with contrast and after passing urine | 22 | $319 | $14 |
| Review by radiologist of urinary bladder image | 21 | $298 | $14 |
| Electronic assessment of bladder emptying | 25 | $93 | $3 |
2017: 19 services
| New patient visit (45+ min) | 80 | $8,630 | $108 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 55 | $6,536 | $113 |
| Return visit (30+ min) | 69 | $6,113 | $67 |
| Diagnostic exam of bladder and urethra using an endoscope | 57 | $4,547 | $77 |
| New patient visit (45+ min) | 33 | $3,696 | $112 |
| Short return visit (20+ min) | 58 | $2,784 | $44 |
| Return visit (30+ min) | 26 | $2,181 | $61 |
| Insertion of device into abdomen with pressure and urine flow rate study | 57 | $2,164 | $36 |
| New patient visit (60+ min) | 14 | $2,030 | $145 |
| Long return visit (40+ min) | 13 | $1,295 | $93 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 57 | $999 | $17 |
| Injection procedure for imaging of bladder during voiding | 42 | $919 | $20 |
| Review by radiologist of urinary bladder image | 58 | $917 | $15 |
| Review by radiologist of urinary bladder and urethra images with contrast and after passing urine | 58 | $908 | $15 |
| Short return visit (20+ min) | 15 | $871 | $46 |
| Short return visit | 34 | $841 | $23 |
| Fitting and insertion of vaginal support device | 11 | $583 | $34 |
| Electronic assessment of bladder emptying | 63 | $269 | $4 |
| Simple bladder irrigation and/or instillation | 13 | $227 | $15 |
2016: 16 services
| New patient visit (45+ min) | 125 | $13,490 | $108 |
| Diagnostic exam of bladder and urethra using an endoscope | 54 | $5,767 | $103 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 63 | $5,635 | $87 |
| Return visit (30+ min) | 45 | $3,362 | $70 |
| Short return visit (20+ min) | 55 | $2,780 | $43 |
| New patient visit (60+ min) | 17 | $2,545 | $150 |
| Insertion of device into abdomen with pressure and urine flow rate study | 66 | $2,437 | $36 |
| Exam with injections of chemical for destruction of bladder using an endoscope | 15 | $2,383 | $125 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 63 | $2,215 | $35 |
| Long return visit (40+ min) | 14 | $1,585 | $99 |
| New patient visit (30+ min) | 17 | $1,153 | $68 |
| Short return visit | 39 | $944 | $22 |
| Review by radiologist of urinary bladder image | 59 | $887 | $15 |
| Review by radiologist of urinary bladder and urethra images with contrast and after passing urine | 56 | $846 | $15 |
| Simple bladder irrigation and/or instillation | 17 | $378 | $21 |
| Electronic assessment of bladder emptying | 72 | $353 | $4 |
2015: 10 services
| New patient visit (45+ min) | 35 | $4,052 | $116 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 22 | $2,224 | $101 |
| New patient visit (60+ min) | 14 | $2,104 | $150 |
| Diagnostic exam of bladder and urethra using an endoscope | 17 | $1,949 | $115 |
| Return visit (30+ min) | 12 | $844 | $70 |
| Insertion of device into abdomen with pressure and urine flow rate study | 22 | $789 | $36 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 18 | $621 | $35 |
| Review by radiologist of urinary bladder image | 16 | $232 | $14 |
| Review by radiologist of urinary bladder and urethra images with contrast and after passing urine | 15 | $222 | $15 |
| Electronic assessment of bladder emptying | 26 | $118 | $4 |
Medicaid work
$366 in 2019
Medicaid paid $366 for 40 billed services this clinician did in 2019, up to 14 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging | 40 | $366 |
| 2019 | 40 | 1 | 14 | $366 |
| 2018 | 29 | 2 | 16 | $787 |
See the largest Medicaid services in earlier years
2018
| Service | 13 | $588 |
| Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging | 16 | $198 |
Drugs they prescribed that Part D paid
$42,315
Pharmacies billed $42,315 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
97 generic and 51 brand-name prescriptions · $42,315 in drug cost · 29 antibiotic prescriptions to 21 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Gemtesa | 24 | $23,728 | $989 |
| Myrbetriq | 16 | $11,404 | $713 |
| Estradiol | 26 | $1,827 | $70 |
| Finasteride | 12 | $198 | $16 |
| Cephalexin | 13 | $65 | $5 |
Year by year
| 2024 | 148 | 67 | None | 34% | $42,315 |
| 2023 | 167 | 58 | 0% (0) | 35% | $51,188 |
| 2022 | 378 | 104 | 0% (0) | None | $114,706 |
| 2021 | 352 | 116 | 0% (0) | 53% | $106,591 |
| 2020 | 713 | 185 | None | 42% | $200,238 |
| 2019 | 903 | 213 | None | 56% | $272,944 |
| 2018 | 682 | 156 | None | 55% | $174,852 |
| 2017 | 904 | 194 | None | 57% | $190,557 |
| 2016 | 635 | 145 | None | 49% | $99,772 |
| 2015 | 384 | 141 | 0% (0) | 61% | $74,426 |
| 2014 | 371 | 142 | None | 58% | $61,862 |
| 2013 | 96 | 59 | 19% (18) | None | $8,775 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 5 drugs
| Gemtesa | 16 | $18,349 | $1,147 |
| Myrbetriq | 28 | $18,044 | $644 |
| Estradiol | 24 | $2,605 | $109 |
| Finasteride | 18 | $298 | $17 |
| Trospium Chloride | 19 | $226 | $12 |
2022: 9 drugs
| Myrbetriq | 95 | $63,017 | $663 |
| Gemtesa | 25 | $22,717 | $909 |
| Premarin | 24 | $10,425 | $434 |
| Methenamine Hippurate | 27 | $3,484 | $129 |
| Estradiol | 25 | $2,664 | $107 |
| Nitrofurantoin | 19 | $1,157 | $61 |
| Finasteride | 38 | $459 | $12 |
| Tamsulosin | 26 | $345 | $13 |
| Cephalexin | 21 | $84 | $4 |
2021: 8 drugs
| Myrbetriq | 120 | $78,085 | $651 |
| Premarin | 22 | $9,067 | $412 |
| Methenamine Hippurate | 31 | $6,203 | $200 |
| Estradiol | 28 | $3,590 | $128 |
| Trospium Chloride | 18 | $1,272 | $71 |
| Finasteride | 31 | $569 | $18 |
| Tamsulosin | 28 | $467 | $17 |
| Cephalexin | 13 | $57 | $4 |
2020: 10 drugs
| Myrbetriq | 228 | $141,548 | $621 |
| Premarin | 39 | $15,126 | $388 |
| Methenamine Hippurate | 53 | $8,680 | $164 |
| Trospium Chloride | 58 | $7,561 | $130 |
| Estradiol | 32 | $6,059 | $189 |
| Oxybutynin Chloride Er | 53 | $1,454 | $27 |
| Tamsulosin | 63 | $1,073 | $17 |
| Finasteride | 41 | $745 | $18 |
| Cephalexin | 29 | $108 | $4 |
| Terazosin | 12 | $106 | $9 |
2019: 14 drugs
| Myrbetriq | 310 | $179,305 | $578 |
| Premarin | 77 | $29,509 | $383 |
| Estring | 23 | $10,528 | $458 |
| Methenamine Hippurate | 60 | $10,311 | $172 |
| Estradiol | 24 | $3,942 | $164 |
| Trospium Chloride | 38 | $3,934 | $104 |
| Estrace | 11 | $3,829 | $348 |
| Trospium Chloride Er | 17 | $3,356 | $197 |
| Oxybutynin Chloride Er | 68 | $2,026 | $30 |
| Tamsulosin | 60 | $1,579 | $26 |
| Finasteride | 42 | $862 | $21 |
| Nitrofurantoin | 12 | $743 | $62 |
| Cephalexin | 47 | $333 | $7 |
| Nitrofurantoin Mono-Macro | 16 | $205 | $13 |
2018: 15 drugs
| Myrbetriq | 221 | $112,414 | $509 |
| Vesicare | 27 | $13,173 | $488 |
| Premarin | 36 | $13,171 | $366 |
| Methenamine Hippurate | 66 | $9,408 | $143 |
| Estring | 13 | $5,691 | $438 |
| Estrace | 15 | $4,781 | $319 |
| Oxybutynin Chloride Er | 44 | $2,362 | $54 |
| Trospium Chloride | 19 | $2,104 | $111 |
| Trospium Chloride Er | 14 | $1,536 | $110 |
| Tamsulosin | 54 | $1,011 | $19 |
| Oxybutynin Chloride | 13 | $938 | $72 |
| Finasteride | 23 | $355 | $15 |
| Sodium Chloride | 18 | $253 | $14 |
| Nitrofurantoin Mono-Macro | 15 | $245 | $16 |
| Cephalexin | 27 | $133 | $5 |
2017: 16 drugs
| Myrbetriq | 310 | $121,815 | $393 |
| Premarin | 40 | $15,060 | $376 |
| Vesicare | 29 | $11,747 | $405 |
| Methenamine Hippurate | 84 | $9,246 | $110 |
| Estrace | 20 | $5,818 | $291 |
| Trospium Chloride | 39 | $5,225 | $134 |
| Oxybutynin Chloride Er | 50 | $2,637 | $53 |
| Trospium Chloride Er | 14 | $2,626 | $188 |
| Tamsulosin | 72 | $1,307 | $18 |
| Nitrofurantoin | 11 | $811 | $74 |
| Nitrofurantoin Mono-Macro | 27 | $598 | $22 |
| Polyethylene Glycol 3350 | 14 | $427 | $30 |
| Oxybutynin Chloride | 14 | $410 | $29 |
| Sodium Chloride | 15 | $160 | $11 |
| Finasteride | 15 | $156 | $10 |
| Cephalexin | 40 | $154 | $4 |
2016: 11 drugs
| Myrbetriq | 201 | $64,958 | $323 |
| Premarin | 22 | $7,745 | $352 |
| Rapaflo | 14 | $2,897 | $207 |
| Oxybutynin Chloride Er | 61 | $2,540 | $42 |
| Trospium Chloride Er | 17 | $2,439 | $143 |
| Trospium Chloride | 26 | $2,317 | $89 |
| Methenamine Hippurate | 23 | $2,265 | $98 |
| Tamsulosin | 101 | $1,656 | $16 |
| Oxybutynin Chloride | 13 | $646 | $50 |
| Cephalexin | 37 | $136 | $4 |
| Sodium Chloride | 11 | $114 | $10 |
2015: 9 drugs
| Myrbetriq | 72 | $21,994 | $305 |
| Vesicare | 51 | $21,650 | $425 |
| Vagifem | 20 | $6,909 | $345 |
| Toviaz | 16 | $3,458 | $216 |
| Premarin | 12 | $3,025 | $252 |
| Tolterodine Tartrate Er | 16 | $3,012 | $188 |
| Nitrofurantoin Mono-Macro | 27 | $818 | $30 |
| Oxybutynin Chloride Er | 13 | $810 | $62 |
| Tamsulosin | 31 | $702 | $23 |
2014: 9 drugs
| Myrbetriq | 59 | $17,267 | $293 |
| Vesicare | 53 | $16,379 | $309 |
| Toviaz | 32 | $7,535 | $235 |
| Premarin | 24 | $5,312 | $221 |
| Gelnique | 11 | $2,342 | $213 |
| Nitrofurantoin Mono-Macro | 28 | $923 | $33 |
| Tamsulosin | 18 | $669 | $37 |
| Ciprofloxacin | 14 | $88 | $6 |
| Cephalexin | 15 | $58 | $4 |
2013: 1 drug
| Oxycodone-Acetaminophen | 11 | $71 | $6 |
Money from drug and device companies
$357 in 2025
| 2025 | 4 | 5 | None | $357 |
| 2024 | 4 | 7 | None | $367 |
| 2023 | 3 | 14 | $5,500 | $6,761 |
| 2022 | 3 | 18 | $2,495 | $6,037 |
| 2021 | 1 | 1 | $500 | $500 |
| 2020 | 1 | 1 | None | $117 |
| 2019 | 1 | 6 | None | $865 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Botox | $172 | 2 payments
|
| Boston Scientific | General - Therapies | $143 | 1 payment
|
| Bluewind Medical | Revi | $25 | 1 payment
|
| Ambu | None | $18 | 1 payment
|
See all 5 published payments
| Bluewind Medical | Meals · 2025-06-13 | Revi | $25 |
| Abbvie | Meals · 2025-04-29 | Botox | $137 |
| Abbvie | Meals · 2025-02-27 | Botox | $35 |
| Ambu | Meals · 2025-01-27 | None | $18 |
| Boston Scientific | Meals · 2025-01-23 | General - Therapies | $143 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $367
| Bluewind Medical | Revi | $148 | 1 payment
|
| Coloplast | Altis | $136 | 3 payments
|
| Boston Scientific | Solyx Sis System | $60 | 2 payments
|
| Medtronic | Interstim | $22 | 1 payment
|
2023: $6,761
| Boston Scientific | Solyx Sis System | $6,621 | 12 payments
|
| Medtronic | Interstim | $115 | 1 payment
|
| Axonics | Axonics | $25 | 1 payment
|
2022: $6,037
| Abbvie | Botox | $3,437 | 5 payments
|
| Urovant Sciences | Gemtesa | $2,426 | 12 payments
|
| Medtronic | Interstim | $174 | 1 payment
|
2021: $500
| Boston Scientific | General - Female Sui | $500 | 1 payment
|
2020: $117
| Medtronic USA | Interstim | $117 | 1 payment
|
2019: $865
| Medtronic USA | Interstim | $865 | 6 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| UROVANT SCIENCES INC · An Exploratory Phase 2a Study Evaluating the Efficacy and Safety of Uro-902 in Subjects With Overactive Bladder and Urge Urinary Incontinence · 2022 | Their institution | $12,825 |
| UROVANT SCIENCES INC · An Exploratory Phase 2a Study Evaluating the Efficacy and Safety of Uro-902 in Subjects With Overactive Bladder and Urge Urinary Incontinence · 2021 | Their institution | $3,832 |
| Sumitomo Pharma America, Inc. · An Exploratory Phase 2a Study Evaluating the Efficacy and Safety of Uro-902 in Subjects With Overactive Bladder and Urge Urinary Incontinence · 2023 | Their institution | $2,880 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1750558193
- Licence
- CA A136792California A136792: Current · expires 2026-12-31
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2088F0040X (2088F0040X); Urology (208800000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2008-05-14
- NPI last updated
- 2024-03-13
- NPI record certified
- 2024-03-13
This is when the NPI record was last certified, not a medical board exam.